Autopsy report · NCT00684996
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Cause of deathNo reason given
Life of this trial
- Ran for about 2 years 4 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 3 years 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Recurrent Renal Cell Cancer; Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
- Interventions
- etaracizumab; bevacizumab
- Participants
- 5
- Sites
- 5
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.